MindWalk Holdings Corp Dossier
Qualitative Analysis
Business overview
MindWalk Holdings Corp. (formerly known as ImmunoPrecise Antibodies Ltd. until its corporate name and ticker change in September 2025) operates as a bio-native artificial intelligence company. The company unifies sequence, structure, function, and literature into a single computational language powered by its patented HYFT technology and LensAI platform. By integrating this computational engine with a full-stack wet laboratory, MindWalk accelerates the discovery and development of biologics, supporting rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics. Its technology is utilized by teams across 19 of the top 20 global pharmaceutical companies to accelerate precision discovery.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Establishing a segregated portfolio structure in the Cayman Islands in collaboration with Walkers Global. This structure houses individual AI-generated assets (such as the GLP-1 and Dengue programs) in ringfenced portfolios, allowing direct asset-level investment while MindWalk retains platform control.
Expected impact: Enables flexible, asset-specific funding, minimizes dilution at the parent level, and facilitates future spin-outs or targeted transactions.
Transitioning from specialized wet-lab services to a scalable intelligence-platform model, emphasizing recurring SaaS offerings and enterprise-level contracts.
Expected impact: Establishes predictable, high-margin recurring revenue streams and improves overall gross margins.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Crucial for designing and establishing the segregated portfolio corporate structure in the Cayman Islands to house AI-driven drug assets.
Terms: Not disclosed